APPLICATION OF DYDROGESTERONE IN THE COMPLEX TREATMENT OF HYPERPROLIFERATIVE PROCESSES OF ENDOMETRIUM IN PATIENTS WITH EXTRAGENITAL PATHOLOGY.
DOI:
https://doi.org/10.11603/24116-4944.2014.2.5865Keywords:
endometrium, hyperplastic processes, extragenital pathology, hormone therapy, pro-gestins.Abstract
Evaluated effects of dydrogesterone on the endometrium in hyperplastic processes in women with extragenital pathology. Metabolic impact of dydrogesterone suggest it as the drug of choice for treatment of benign hyperplastic processes of the endometrium in women with extragenital pathology. The positive clinical and morphological effects of cyclical dydrogesterone useing from 5 th to 25 th day of the menstrual cycle at a dose of 20 mg daily for at least 6 months. Indicators of Ca2+, Mg2+ATP activity of endoplasmic reticulum of endometrium and levels of nitric oxide in serum can be considered as criteria for the efficacy of hormone therapy.
References
Patolohyya sheyky y tela matky. Rukovodstvo dlya vrachey / Pod redaktsyey prof. Kokhanevych E.V. - Nezhyn: Hydromaks, 2009. - S. 174-350.
Schindler A.S. Progestins and endometrial cancer //Ginecol. Endocrinol.- 2001. - V. 15, № 6. - P. 29 - 37.
De Lignires D. Endometrial hyperplasia. Risk, recognition and the search for the safe hormone replacement regiment//J Reprod Med. - 1999. - №44(2). - P. 191-196.
Hyperplazyya éndometryya: éffektyvnostʹ lechenyya pry pomoshchy naturalʹnoho mykronyzyrovannoho prohesterona, prymenyaemoho vahynalʹno/ B. Shymanska, A. Hardyshevska, Y. Pabykh, K. Chaykovsky/ZPrzeglad menopauzalny Obzor menopauzalʹnyy. - 2006. - №2. - S.75-79.
Sravnytelʹnaya éffektyvnostʹ kompleksnoy terapyy hyperplastycheskykh protsessov éndometryya u bolʹnykh s razlychnoy tekhnohennoy nahruzkoy sredy prozhyvanyya / R.A. Rodkyna, L.YU. Davydyan, A.YU. Bohdasarov, L.S. Tselkovych // Akush. y hynekol. — 2002. — № 1. — S. 52 - 54.
Marsden DN, Hacker NF. Optimal management of endometrium hyperplasia // Best Pract Res Clin Obstet
Gynaecol/ - 2001. - №15(3). - P.393-405.
Sitruk - Ware R. Progestogens in hormonal replacement therapy: new molecules, risk and benefits // Menopause. - 2002. - №9(1). - P.6-15.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
